Benitec Biopharma (BNTC) Common Equity (2019 - 2025)
Benitec Biopharma (BNTC) posted Common Equity of $187.4 million for Q4 2025, up 100.17% sequentially from $93.6 million in Q3 2025, and up 27332.7% YoY from N/an in Q4 2024.
Benitec Biopharma (BNTC) Common Equity (2019 - 2025) Analysis & Trends
Benitec Biopharma has reported Common Equity for 7 years, with the latest figure at $187.4 million in Q4 2025.
- Quarterly Common Equity rose 27332.7% year-over-year to $187.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $187.4 million (up 27332.7% YoY) and the FY2025 annual result came in at $97.3 million, up 105.92% from the prior year.
- Common Equity improved to $187.4 million in Q4 2025 per BNTC's latest filing, from $93.6 million in the prior quarter.
- Over five years, Common Equity peaked at $260.5 million in Q3 2024 and troughed at -$219.4 million in Q1 2025.
- A 5-year average of $30.6 million and a median of $13.1 million in 2022 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 27332.7% in 2025, down 2007.57% in 2025.
- Over 5 years, Common Equity stood at $10.8 million in 2021, then slipped by 17.0% to $9.0 million in 2022, then jumped by 72.0% to $15.5 million in 2023, then sank by 104.45% to -$688000.0 in 2024, then jumped by 27332.7% to $187.4 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $187.4 million, $93.6 million, and $97.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Benitec Biopharma | 577.39 Mn | 388.49 Mn | - | 187.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 187.36 Mn |
| Sep 30, 2025 | 93.60 Mn |
| Jun 30, 2025 | 97.30 Mn |
| Mar 31, 2025 | -219.37 Mn |
| Dec 31, 2024 | -688,000.00 |
| Sep 30, 2024 | 260.49 Mn |
| Jun 30, 2024 | 47.25 Mn |
| Mar 31, 2024 | 11.50 Mn |
| Dec 31, 2023 | 15.47 Mn |
| Sep 30, 2023 | 22.31 Mn |
| Jun 30, 2023 | 202,000.00 |
| Mar 31, 2023 | 4.71 Mn |
| Dec 31, 2022 | 8.99 Mn |
| Sep 30, 2022 | 14.61 Mn |
| Jun 30, 2022 | 2.88 Mn |
| Mar 31, 2022 | 7.52 Mn |
| Dec 31, 2021 | 10.84 Mn |
| Sep 30, 2021 | 15.48 Mn |
| Jun 30, 2021 | 20.01 Mn |
| Mar 31, 2021 | 10.93 Mn |